Literature DB >> 27407090

Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis.

Jamila Al-Azhri1,2, Yali Zhang2, Wiam Bshara3, Gary Zirpoli2, Susan E McCann2, Thaer Khoury3, Carl D Morrison3, Stephen B Edge4, Christine B Ambrosone2, Song Yao5.   

Abstract

PURPOSE: Our previous work has shown low serum 25-hydroxyvitamin D concentrations in association with aggressive breast cancer subtypes. Vitamin D receptor (VDR) is central for vitamin D-mediated transcription regulation. Few studies have examined breast VDR expression with tumor characteristics or patient survival. EXPERIMENTAL
DESIGN: VDR expression in breast tumor tissue microarrays was determined by immunohistochemistry in 1,114 female patients as low, moderate, and strong expression based on an immunoreactive score, and examined with histopathologic tumor characteristics and survival outcomes including progression-free survival, breast cancer-specific survival, and overall survival.
RESULTS: A majority (58%) of breast tumors showed moderate or strong VDR expression. VDR expression was inversely related to aggressive tumor characteristics, including large tumor size, hormonal receptor (HR) negativity, and triple-negative subtype (P < 0.05). In addition, VDR expression was also inversely related to Ki-67 expression among patients older than 50 years. Nevertheless, VDR expression was not associated with any patient survival outcomes examined.
CONCLUSIONS: In a large patient population, VDR expression is inversely associated with more aggressive breast cancer, but not with breast cancer survival outcomes. The present findings of VDR expression are consistent with our previous results of circulating vitamin D biomarkers, which provide two converging lines of evidence supporting the putative benefits of vitamin D against aggressive breast cancer. Because of the observational nature of our analyses, future studies are warranted to establish the causality of the reported associations. Clin Cancer Res; 23(1); 97-103. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27407090      PMCID: PMC5213876          DOI: 10.1158/1078-0432.CCR-16-0075

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  Expression of VDR and CYP24A1 mRNA in human tumors.

Authors:  Mark G Anderson; Masaki Nakane; Xiaoan Ruan; Paul E Kroeger; J Ruth Wu-Wong
Journal:  Cancer Chemother Pharmacol       Date:  2005-09-23       Impact factor: 3.333

2.  Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen.

Authors:  J Abe-Hashimoto; T Kikuchi; T Matsumoto; Y Nishii; E Ogata; K Ikeda
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

3.  Vitamin D regulates the phenotype of human breast cancer cells.

Authors:  Natalia Pendás-Franco; José Manuel González-Sancho; Yajaira Suárez; Oscar Aguilera; Andreas Steinmeyer; Carlos Gamallo; María T Berciano; Miguel Lafarga; Alberto Muñoz
Journal:  Differentiation       Date:  2006-12-11       Impact factor: 3.880

4.  Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer.

Authors:  Michael Friedrich; Roland Axt-Fliedner; Carlos Villena-Heinsen; Wolfgang Tilgen; Werner Schmidt; Jörg Reichrath
Journal:  Histochem J       Date:  2002 Jan-Feb

5.  Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.

Authors:  R J Frampton; L J Suva; J A Eisman; D M Findlay; G E Moore; J M Moseley; T J Martin
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

6.  Vitamin D receptors in breast cancer cells.

Authors:  R R Buras; L M Schumaker; F Davoodi; R V Brenner; M Shabahang; R J Nauta; S R Evans
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Genetic variants in the vitamin D pathway and breast cancer disease-free survival.

Authors:  Mala Pande; Patricia A Thompson; Kim-Anh Do; Aysegul A Sahin; Christopher I Amos; Marsha L Frazier; Melissa L Bondy; Abenaa M Brewster
Journal:  Carcinogenesis       Date:  2012-11-24       Impact factor: 4.944

Review 8.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

9.  Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study.

Authors:  Song Yao; Lara E Sucheston; Amy E Millen; Candace S Johnson; Donald L Trump; Mary K Nesline; Warren Davis; Chi-Chen Hong; Susan E McCann; Helena Hwang; Swati Kulkarni; Stephen B Edge; Tracey L O'Connor; Christine B Ambrosone
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

10.  Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.

Authors:  A Thakkar; B Wang; M Picon-Ruiz; P Buchwald; Tan A Ince
Journal:  Breast Cancer Res Treat       Date:  2016-04-27       Impact factor: 4.872

View more
  27 in total

Review 1.  Function of the vitamin D endocrine system in mammary gland and breast cancer.

Authors:  JoEllen Welsh
Journal:  Mol Cell Endocrinol       Date:  2017-06-01       Impact factor: 4.102

2.  Vitamin D Status and VDR Polymorphisms as Prognostic Factors in Differentiated Thyroid Carcinoma.

Authors:  Andra-Maria Cocolos; Andrei Muresan; Andra Caragheorgheopol; Mircea Ghemigian; Dumitru Ioachim; Catalina Poiana
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

3.  Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression.

Authors:  Giorgia Centonze; Dora Natalini; Alessio Piccolantonio; Vincenzo Salemme; Alessandro Morellato; Pietro Arina; Chiara Riganti; Paola Defilippi
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

4.  Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma.

Authors:  R Sánchez-Céspedes; M D Fernández-Martínez; A I Raya; C Pineda; I López; Y Millán
Journal:  BMC Vet Res       Date:  2021-05-25       Impact factor: 2.741

5.  Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients.

Authors:  Xi Zhang; Simone Hofmann; Brigitte Rack; Nadia Harbeck; Udo Jeschke; Sophie Sixou
Journal:  Int J Mol Sci       Date:  2017-06-20       Impact factor: 5.923

6.  Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.

Authors:  Sabine Heublein; Doris Mayr; Alfons Meindl; Alexandra Kircher; Udo Jeschke; Nina Ditsch
Journal:  J Exp Clin Cancer Res       Date:  2017-04-20

7.  PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer.

Authors:  Naoko Ishida; Motoi Baba; Yutaka Hatanaka; Kanako Hagio; Hiromi Okada; Kanako C Hatanaka; Kenichi Togashi; Yoshihiro Matsuno; Hiroko Yamashita
Journal:  Oncotarget       Date:  2018-04-03

Review 8.  Vitamin D as a Potential Preventive Agent For Young Women's Breast Cancer.

Authors:  Sarah M Bernhardt; Virginia F Borges; Pepper Schedin
Journal:  Cancer Prev Res (Phila)       Date:  2021-07-09

9.  Knocking out the Vitamin D Receptor Enhances Malignancy and Decreases Responsiveness to Vitamin D3 Hydroxyderivatives in Human Melanoma Cells.

Authors:  Ewa Podgorska; Tae-Kang Kim; Zorica Janjetovic; Krystyna Urbanska; Robert C Tuckey; Sejong Bae; Andrzej T Slominski
Journal:  Cancers (Basel)       Date:  2021-06-22       Impact factor: 6.639

10.  Vitamin D exposure and Risk of Breast Cancer: a meta-analysis.

Authors:  Nuria Estébanez; Inés Gómez-Acebo; Camilo Palazuelos; Javier Llorca; Trinidad Dierssen-Sotos
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.